Motivation to perform presymptomatic testing in portuguese subjects at-risk for late-onset genetic diseases by Leite, Ángela et al.
resUMen
El papel del psicólogo clínico en el contexto
del consejo genético incluye brindar apoyo a los
sujetos en riesgo en el proceso de toma de deci-
siones, independientemente de la decisión adop-
tada por el sujeto (conociendo o no el resultado de
las pruebas genéticas).
El estudio que se informa aborda la motivación
para realizar las pruebas pre-sintomáticas (PPS)
de sujetos en situación de riesgo para tres enfer-
medades: polineuropatía amiloide familiar (PAF),
la enfermedad de Huntington (EH) y la enferme-
dad de Machado-Joseph (EMJ) y comparar con la
motivación para realizar las PPS para hemocro-
matosis (HH).
La muestra consistió en 213 sujetos portugue-
 ses que tenían riesgo genético para contraer las tres
enfermedades y 31 sujetos en situación de ries go
genético para contraer hemocromatosis. Ellos fue-
ron evaluados con una entrevista para ob tener da-
tos sociodemográficos y debían responder a una
pregunta sobre la motivación para llevar a cabo las
pruebas pre-sintomáticas. 
Se obtuvieron siete categorías principales y
las las siguientes son las más significativas para
PAF, EH y EMJ: razones relacionadas con el fu-
turo, razones relacionadas con los demás y razo-
nes relacionadas con la curiosidad y la necesidad
de conocer. Para hemocromatosis, las más impor-
tantes resultaron ser razones relacionadas con los
demás y las relacionadas con las características de
la enfermedad.
La motivación para realizar el test pre-sinto-
mático (PST) de la PAF, EH y EMJ es externa y
sin relación con la enfermedad, mientras que la
motivación de los sujetos en situación de riesgo
para la HH está relacionada con la enfermedad.
Las razones relacionadas con los demás es una
motivación común en ambos grupos. A los sujetos
también les preocupa la posibilidad de  transmitir
la enfermedad a sus hijos.
Palabras clave: Pruebas pre-sintomáticas (PPS);
Enfermedad genética; Sujetos en situación de
riesgo; Polineuropatía amiloide familiar (PAF)
TTR V30M; Enfermedad de Huntington (EH);
Enfermedad de Machado-Joseph (EMJ).
aBstraCt
The role of the clinical psychologist in the
context of genetic counseling includes support for
the process of decision-making for subjects at-risk,
regardless of the decision that was made. For this,
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it is important to know the motivations behind
these decisions. What may be considered advant -
ageous and justifiable reasons to perform the PST
for genetic diseases from the medical and public
point of view, i.e., planning for the future, helping
in the choice of a profession, family planning,
improving quality of life and contributing to health,
may not be recognized as such by the individual
seeking the PST.
This study addresses the motivation to perform
the presymptomatic testing (PST) of subjects at-
risk for three diseases, Familial Amyloid Poly- 
neuro pathy (FAP), Huntington’s disease (HD), and
Machado-Joseph disease (MJD), compared with
the motivation to perform the PST for Hemo -
chromatosis (HH). 
FAP, HD and MJD are three genetic (monogen -
ic) autosomal dominant late-onset diseases (LON-
Ds) with no cure. FAP is a progressive sensorimotor
and autonomic neuropathy of adult hood. HD is
characterized by a triad of clinical symptoms of
chorea (motor, cognitive and psy chiatric sympt -
oms), emotional distress and cogn itive decline.
MJD is characterized by slowly progressive clum -
siness in the arms and legs, a staggering lurching
gait, sometimes mistaken for drunkenness, dif -
ficulty with speech and swallow ing, involuntary
eye movements, and may be accompanied by
double vision or bulging eyes, and lower limb
spasticity. HH is a disease in which too much iron
accumulates in parenchymal organs, leading to iron
overload and subsequent organ toxicity and failure.
The study participants consisted in 213 subjects
at genetic risk for FAP, HD, and MJD and 31
subjects at genetic risk for HH, that were assessed
through an interview to obtain sociodemographic
data and the answer to one question about
motivation to perform PST: “Which were the
reasons that led you to perform the predictive test?”
This study was carried out in Center for Predictive
and Preventive Genetics (CGPP), Institute for
Molecular and Cell Biology (IBMC), Porto (Por -
tugal). This research used a mixed-method, since
qualitative and quantitative techniques of data
analysis were used.
Before deciding to seek genetic counseling and
to know their genetic status, subjects at-risk have
naturally considered their motives and it was
probably the pro-counseling reasons the ones
dictating the motivation to perform the PST. This
may suggest that in fact there is a prior self-
selection to the test, i.e. only those considering to
have emotional skills to go through the process,
performing the test. 
Seven major categories were obtained. The
most significant ones for FAP, HD and MJD were
reasons related to the future, reasons related to
others and reasons related to curiosity and to the
need to know. For HH, the most important ones
were reasons related to others and reasons related
to the characteristics of the disease. 
The motivation of subjects at-risk to perform
the PST for FAP, HD and MJD is external and
unrelated to the disease, while the motivation of
subjects at-risk to perform the PST for HH is
related to the disease. Reasons related to others are
a common motivation: as subjects at-risk for FAP,
HD and MJD, subjects at-risk for HH also chose
reasons related to others as one of the most
important motivations to carry out the PST. These
subjects also care about the fact that they can
transmit the disease to their children and care about
other family members which are already ill. The
category reasons related to others includes sub -
categories that identify the person and the situation
that led to the decision to perform a PST. Subjects
at-risk are also concerned about the fact that they
have to decide whether or not to have children and
its economic implications. 
Key words: Motivation to perform the PST; Gen -
etic diseases; Subjects at-risk; Familial Amyl oid
Poly neuropathy (FAP); TTR; V30M; Hunting ton’s
disease (HD); Machado-Joseph disease (MJD). 
introduction
The subset of psychological issues and
proc esses that are most salient within the
clinical genetics context has evolved and it
must take into consideration the potential
costs but also the benefits since psychologists
can play a critical role, assisting patients,
families, physicians, and policymakers as
they grapple with the complex task of inte-
grating genetic information into their profes-
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sional practice and everyday lives (Lerman,
Croyle, Tercyak, & Hamann, 2002). The role
of the clinical psychologist in the context of
genetic counseling includes support for the
process of decision-making for subjects at-
risk, regardless of the decision that was
made. For this, it is important to know the
motivations behind these decisions. This
study will enable to know the reasons why
subjects at-risk for Familial Amyloid Poly -
neuropathy (FAP), Huntington’s Disease
(HD), and Machado-Joseph Disease (MJD)
want to perform the PST and compare the re-
sults with the motivations of the subjects at-
risk for Hereditary Hemochromatosis (HH)
which also wish to carry the presymptomatic
testing (PST).
the studied diseases
FAP, HD and MJD are three genetic (mon -
 o genic) autosomal dominant late-onset dis-
eases (LONDs) with no cure. 
FAP, also known by Transthyretin (TTR)
Amyloid Neuropathy or even Transthyretin
(TTR) Amyloid Polyneuropathy (since the
three terms are considered synonyms) is a
progressive sensorimotor and autonomic
neuropathy of adulthood (Adams, 2013) and
is caused by mutations in the TTR gene
(18q12.1). FAP is a rare and fatal systemic
disease resulting from autosomal dominant
inherited single-point mutations (Coutinho et
al., 2013). FAP is presented in many different
forms, with considerable phenotypic varia-
tion across individuals and geographic loca-
tions. Diagnosis can be challenging and treat- 
ment often requires a multidisciplinary ap-
proach. Physicians likely to diagnose and
treat patients with this disease include neu-
rologists, cardiologists, gastroenterologists,
ophthalmologists, and other specialists (An -
do et al., 2013). The age of onset varies be-
tween the 20s and the 90s (Seca, Ferreira, &
Coelho, 2014). Lemos and colleagues (2014)
consider that early-onset (≤ 40 years) and
later-onset (≥ 50 years) cases of TTR-FAP
V30M are not different entities, often coex-
isting in the same family, and showing antic-
ipation, with earlier age-at-onset in younger
generations, usually associated with more se-
vere phenotype. Acknowledgment of antici-
pation may have important clinical impli- 
ca tions in genetic counselling of offspring and
in follow-up of mutation carriers (Lemos et
al., 2014). The largest cluster of individuals
with TTR-FAP caused by the Val 30Met mu-
tation is found in northern Portugal, particu-
larly in Póvoa de Varzim and Vila do Conde,
where the incidence is estimated to be one in
538 individuals (Conceição & De Car valho,
2007), i.e., one in every 1,000 individuals has
the disease, and one in every 538 are carriers
of the mutated gene.
HD is an adult-onset, fatal genetic disease
with psychosocial implications (Kessler &
Bloch, 1989), since it is a disease in which
nerve cells degenerate. It is characterized by
a triad of clinical symptoms of chorea (mo t-
or, cognitive and psychiatric symptoms),
emo t ional distress and cognitive decline (Lee,
Hwang, Ryu, Kowall, & Ryu, 2014). The
gene responsible for HD is located near the
terminus of the short arm of chromosome 4
and the defect causes a part of DNA, called a
CAG repeat, to occur many more times than
it is supposed to (Kirkwood, Siemers, Hodes,
Conneally, Christian, & Foroud, 2000). There
are basically two forms of HD but the adult-
onset HD is the most common one (Ross et
al., 2014). There is no cure for HD (van
Dellen, Blakemore, Deacon, York, & Hannan,
2000). There is currently no known way to
stop the disease from getting worse. The goal
of treatment is to slow the symptoms and help
the person to function for as long as possible. 
MJD, also called spinocerebellar ataxia
Type 3 (SCA3), is one of approximately 30
recognized, dominantly inherited forms of
ataxia. Ataxia is a common used term mean-
ing lack of muscle control or coordination
(Bettencourt & Lima, 2011). MJD is charac-
terized by slowly progressive clumsiness in
the arms and legs, a staggering lurching gait,
sometimes mistaken for drunkenness, diffi-
culty with speech and swallowing, involun-
tary eye movements, and may be accomp- 
anied by double vision or bulging eyes, and
lower limb spasticity (D’Abreu et al., 2010).
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Some individuals develop dystonia symp-
toms, sustained muscle contractions that
cause twisting of the body and limbs, repeti-
tive movements, and abnormal postures, or
symptoms similar to those of Parkinson’s dis-
ease (D’Abreu et al., 2010). Persons with
MJD have the same disease gene mutation, a
DNA repeat expansion in the ATXN3 gene
(Bettencourt & Lima, 2011). MJD is consid-
ered to be incurable (Rolim, Zagalo-Cardoso,
Paúl, Sequeiros, & Fleming, 2006), but some
symptoms of the disease can still be treated.
Levodopa therapy (van Alfen et al., 2001),
used in treating individuals with Parkinson’s
disease, can ease parkinsonian features, stiff-
ness and slowness of movements, often ac-
companied by a tremor, for many years. 
HH is a disease in which too much iron
accumulates in parenchymal organs, leading
to iron overload and subsequent organ toxic-
ity and failure (Fleming & Sly, 2002). The
gradual accumulation of iron can severely af-
fect most of body’s organs, but especially the
liver, pancreas and heart (Eng, Taylor, Reyes,
Raaka, Berger, & Kowdley, 2005). The ex-
cess of iron in the liver can cause an enlarged
liver, liver failure, liver cancer, or cirrhosis.
The excess of iron in the pancreas can lead
to diabetes and in the heart it can cause ir-
regular heartbeats called arrhythmias and
heart failure (Philippot, 2002). The two ex-
isting types of HH are primary and second-
ary. Primary HH is caused by a defect in the
genes that control the amount of iron ab-
sorbed from food (Yen, Fancher, & Bowlus,
2004). Secondary HH usually is the result of
another disease or condition that causes iron
overload. Primary HH is also a genetic dis-
ease and the treatment is commonly through
phlebotomy for removal of excess iron store
(Salgia & Brown, 2015).
Motivation to PerForM tHe Pst For genetiC
diseases
What may be considered advantageous
and justifiable reasons to perform the PST for
genetic diseases from the medical and public
point of view, i.e., planning for the future,
helping in the choice of a profession, family
planning, improving quality of life and con-
tributing to health, may not be recognized as
such by the individual seeking the PST
(Fleming & Lopes, 2000).
Several studies regarding the motivation
to perform PST for neurogenetic diseases and
the underlying decision-making process have
been carried out. Acording to Schuler-Fac -
cini, Osorio, Romariz, Paneque, Sequei ros,
and Jardim (2014), the decision to undergo
PST for late-onset neurological diseases is
mainly a question of awareness and accessi-
bility. Rodrigues and colleagues (2012) con-
cluded that this decision seems to be
genuinely autonomous, since after genetic
counseling half of the individuals who asked
for PST decided in favour of it and half de-
cided against it. Meissen, Mastromauro, Kie -
ly, McNamara, and Myers (1991) found that
the reasons to perform the test are related
with the reduction of anxiety and the uncer-
tainty associated with being at-risk, and en-
hanced planning and decision making. The
emotional aspects and the perception of per-
sonal risk, i.e., the subjective risk, seem to
further influence the decision of performing
the genetic test rather than the knowledge re-
lating the precise genetic risk (Zagalo-Car -
doso & Rolim, 2005). The socio-emotion al
skills, understood as a set of knowledges,
skills and attitudes necessary to understand,
express and manage emotional phenomena
(Mikulic, Crespi, & Radusky, 2015) are cru-
cial in the decision to undergo the PST.
For Lucas (1998), the most common rea-
son for undertaking the testing for HD was to
make plans for the future; the wish to know
before a future planned marriage, or remar-
riage; the wish to know before starting a fam-
ily, or having further children; to make career
decisions; to inform one’s children of their
risk status, and to alleviate the dissonance
caused by not knowing one’s HD status. The
intolerance of uncertainty is defined as a
characteristic arrangement resulting from a
set of negative thoughts about uncertainty
(Brenlla & Rodríguez de Behrends, 2015).
According to Meiser and Dunn (2000), be-
tween 40 and 79% of people at-risk of devel-
leite, dinis, sequeiros, and paúl
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oping HD reported the intention to use the test
and found different age-related motives for
HD testing: one being a reproductive risk de-
cision and another one the intention to clarify
the risk for their children. On the other hand,
Wahlin and colleagues (2000) found that sub-
jects at-risk for HD showed high suicidal
ideation and self-injurious behavior and
30.8% of the HD carriers reported suicide or
suicide attempts in the family, whereas the
corresponding figure for HD non-carriers
was 14.3%. These data raise greater concern
about the subjects at-risk for HD seeking ge-
netic counseling.
At-risk symptomatic adult family mem-
bers of FAP may seek testing in order to
make personal decisions regarding reproduc-
tion, financial matters, and career planning.
Others may have different motivations in-
cluding simply the need to know (Sekijima,
Yoshida, Tokuda, & Ikeda, 2001). In FAP
context, the adhesion to the test has been
clearly influenced by the possibility of per-
forming the liver transplant, a therapeutic
modality that allows to halt the progression
of the disease. Many subjects at-risk point as
the main reason for performing the genetic
test the possibility of being able to make an
early registration regarding the waiting list
for transplantation, in case the test result is
positive (Zagalo-Cardoso & Rolim, 2005). 
Rolim and colleagues (2006) concluded
that the decision to undergo the PST for MJD
generates emotional distress and involves
major personal issues, with the potential for
short- to long-term psychological conse-
quences for the individual and the family.
However, the same authors agreed that hav-
ing PST for MJD included a reduction in the
level of uncertainty and the chance to plan
their future, with regard to procreation and to
the disease itself; the possibility of inform-
ing the offspring about the risk of develop-
ing the disease or even the chance of
begin ning a medical treatment, not yet avail-
able, to prevent its development and / or to
delay its course. Cruz-Mariño and colleagues
(2013) refer as main reasons to perform the
PST for SCA2 the risk assessment in the sub-
jects’at-risk descendants, and the physical
and psychological preparation to cope with
the disease and to plan the future. The au-
thors did not include subjects at-risk for
MJD, but for SCA2, a genetically different
condition, nonetheless their clinical distinc-
tion with MJD / SCA3 may at times be diffi-
cult to make. 
oBJeCtive
The aim of this research was to know the
motivation to perform the PST of subjects at-
risk for FAP, HD, and MJD, and then to com-
pare the results obtained with the motivations
to perform the PST that subjects at-risk for
HH have. 
Methodology
PartiCiPants
The study participants consisted of two
groups: individuals with a priori genetic risk
of 50% for FAP, HD, or MJD diseases, al-
though asymptomatic, aged over 17 years
and subjects at-risk for HH, the group to
which the results will be compared with,
whose risk differs from case to case, also
aged over 17 years. The subjects which were
17 years-old at the time the research was
done were allowed to participate in the study,
as long as they would already have 18 years-
old at the time they received the test result.
Many subjects at-risk are emigrants, enjoy-
ing their vacations in  and taking that time to
perform the PST. They would be told about
the genetic status later.
The first group, the clinical one, consisted
of 213 subjects at genetic risk: 174 subjects
at-risk for FAP, 34 subjects at-risk for HD
and only 5 subjects at-risk to MJD. Age 
(t = 36.328; df = 212; p = .000), gender 
(t = 41.720; df = 212; p = .000), nationality 
(t = 62.619; df = 212; p = .000), education 
(t = 42.219; df = 212; p = .000), and disease 
(t = 52.433; df = 212; p = .000), were distin-
guishable from a statistical point of view,
where t is the Student t Distribution, df is the
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Degrees of Freedom and p is the p value. The
second group, acting as the comparison
group, consisted of 31 subjects at genetic risk
for HH. Age (t = 17.499; df = 30; p = .000),
gender (t = 23.242; df = 30; p = .000), and
education (t = 13.493; df = 30; p = .000),
were distinguishable from a statistical point
of view. Regarding nationality, all these 31
subjects are Portuguese (see Table 1).
Subjects at-risk for HH were chosen to in-
corporate the comparison group because
these subjects were also at-risk for a genetic
disease, although with a different risk and
less severe and limited disease. HH presents
possible treatment and patients may live a
long time with the disease, unlike the other
three diseases, FAP, HD, and MJD.
None of the subjects at-risk, either be-
longing to the clinical or the comparison
group, had previously done the PST. Inclu -
sion criteria in the counseling program were
the following: being at-risk for diseases for
which a direct relative has a molecular diag-
nosis (1); being adulthood (2); and express-
ing the desire to perform the PST, even when
counseling was suggested by the family doc-
tor (3).
MeasUres
All the individuals at genetic risk for FAP,
HD, MJD and HH were assessed through an
interview, to which the participants answered
orally, in order to obtain socio-demographic
data and the answer to an open-ended ques-
tion relating the motivation to perform de
PST: “Which were the reasons that led you
to perform the predictive test?”.
ProCedUres
This study took place in Centre for Pre -
ventive and Predictive Genetics (CGPP),
which is an integrated research centre at the
Institute for Molecular and Cell Biology
(IBMC) (Porto - Portugal). In this research
centre, genetic counseling is available for
LOND’s, mostly, FAP, HD and MJD. This
study has been reviewed and approved by the
IBMC ethics committee. All subjects at-risk
attending consultations for genetic counsel-
ing in the CGPP, in order to know their ge-
netic risk for FAP, HD and MJD, or HH,
were contacted to participate in the study.
Those who agreed to do it, were interviewed
by the authors before the first consultation of
the genetic counseling program. The inten-
tion was to understand the motivations that
drive the subjects at-risk to perform the PST,
aiming to know their genetic status for dis-
eases for which they are at-risk for. All sub-
jects were informed about the nature of the
research, the aims of the study and the type of
treatment to give to the data. The confiden-
tiality of the data was guaranteed and the in-
formed consent to voluntary collaborate in
the research was obtained. This study took
place between 2013 and 2015.
data analysis
This study used a mixed-method, since
qualitative and quantitative techniques of
data analysis were used. Initially, an analysis
of the responses of the participants was car-
ried out through the data analysis software
package NVivo (QSR I, 2012). After the data
collection, the authors have separated the an-
swers according to the disease being studied.
Based on the Grounded Theory Methodology
(Glaser & Strauss, 1967), response patterns
have emerged and categories and, in some
cases, sub-categories, have been established.
As a result, a set of general categories and an-
other set of specific categories were created.
Then, the frequencies of categories were as-
sess ed to obtain a hierarchy of importance,
since the most frequently reported categories
would be the most representative and signif-
icant ones.
results
The open-ended question “Which were
the reasons that led you to perform the pre-
dictive test?” has provided clear answers and
leite, dinis, sequeiros, and paúl
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has also revealed prior reflection regarding
the same question. Seven categories have
emerged: reasons related to the future, rea-
sons related to others, reasons related to cu-
riosity and the need to know, reasons related
to the characteristics of the disease, reasons
related to metaphors about the disease, rea-
sons related to other diseases, and reasons re-
lated to other reasons.
The motivations for subjects at-risk to per-
form the PST related to the future include
planning the future, for example, marrying,
having children, making decisions regarding
professional life and financial issues, etc., and
how these subjects will in the future deal and
manage the disease - for example, whether to
seek professional assistance or preferring to
be cared for by their families, etc. 
Motivations resulting from others relate to
concerns felt in relation to family members
who are already ill, such as the parents, un-
cles, cousins, brothers, etc., and those that
may get ill, especially sons and nephews, in
addition to others who will be affected by the
fact that the subject at-risk is likely to have
the disease, namely, spouses or companions.
The motivations that arise from the  curiosity
and the need to know consist mainly in issues
related to stress management by reducing un-
certainty and own curiosity about the genetic
status-carrier or non-carrier. The specific
characteristics of the disease itself also con-
stitute reasons for carrying out PST, e.g.,
symptoms that are perceived in the other can
be experienced by the subjects at-risk, and
often these subjects reported having symp-
toms that are actually not confirmed, or they
would not be in the PST protocol. The
metaphors that subjects at-risk have about
the diseases for which they are at-risk origi-
nate the conducting of the PST, since what
they know about the disease makes the sub-
jects at-risk preoccupied and anxious. The
reasons related to other diseases to perform
the PST are connected with the fact that sub-
jects at-risk want to understand the symp-
toms that have been associated with the
disease for which they are at-risk for or pre-
vious diseases, because this ambivalence in-
tensifies the uncertainty and anxiety. Finally,
all isolated and specific motivations of each
case were categorized in other reasons. 
From the above reported seven categories,
three can be considered significant for sub-
jects at-risk for FAP, HD and MJD: Reasons
related to the future, Reasons related to oth-
ers, Reasons related to curiosity and the need
to know, while the motivation of the subjects
at-risk for HH is Related to the characteris-
tics of the disease. Reasons related to others
are a common motivation to all diseases (see
Table 2).
With regard to the first category, Reasons
related to the future, the subjects at-risk for
neurodegenerative diseases are the ones who
mainly seek more PST for reasons connected
with the future: 80% for the subjects at-risk
for MJD, 66.7% for the subjects at-risk for
FAP and 58.8% for the subjects at-risk for
HD. Subjects at-risk for HH present a lower
value, 19.4%. Overall, the main reasons that
lead people to want to perform PST, when
considering the future, are: (a) to take pre-
ventive measures (44 references) (e.g., “I
want to perform the PST because I want to
prevent the disease”); (b) to be pregnant, to
have children (e.g., “I want to perform the
PST because I want to have children but I do
not want them to have the disease”); (c) to
organize life, to make decisions, to choose
(36 references each) (e.g., “I want to know if
I have the disease or not because I would like
to invest in a business and I do not know if I
should do it if I have the disease”). 
When analysing each disease separately, it
is possible to conclude that priorities de-
scribed above coincide for subjects at-risk for
FAP. The same applies to the subjects at-risk
for HD, which, in addition to these aspects,
also seek to have a more peaceful life and
therefore want to know the result of the PST.
Subjects at-risk of MJD take special care in
organizing life, while subjects at-risk for HH
seek essentially to take preventive measures.
Regarding the second category, Reasons
related to others, most of the subjects at-risk
for HH searched genetic counseling because
of another person, and the same happens with
subjects at-risk for FAP. Subjects at-risk for
HD and for MJD were influenced by third
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parties to seek genetic counseling in order to
carry out the PST, but fewer in number than
the former. It is important to distinguish in
this category between wishing to take the
PST because subjects at-risk felt they were
driven to it by someone else, and to want to
perform the PST because somebody else is
pressing them to do it. Therefore, this partic-
ular category was also divided into other sub-
categories given its complexity: Because of
someone else (e.g., “I would like to know be-
cause of my son / daughter”), Instigated by
others (e.g., “My family doctor told me to
perform the PST”), Because someone has the
disease (e.g., “I want to perform the PST be-
cause my aunt has the disease and I want to
know if I also have it”), and Because some-
one died with the disease (e.g., “My mother
died of the disease and I want to know if I
will also have it”) (see Table 3). In the sub-
category Because of someone else, sons /
daughters and brothers / sisters emerge as the
key drivers behind the completion of PST.
With regard to the subcategory Instigated by
others, and in relation to the subjects at-risk
for FAP, brothers / sisters are mainly the ones
who play the instigator role. In relation to the
subjects at-risk for HH, mainly doctors (13
references) act as instigators. For the subcat-
egory Because someone has the disease, and
with regard to the subjects at-risk for FAP,
brothers / sisters and the mother emerge as
patients, while the subjects at-risk for HH
refer, above all, parents and children, source
of concern. Finally, and regarding the sub-
category Because someone died with the dis-
ease, the subjects at-risk for FAP mainly refer
parents, while subjects at-risk for HH refer
above all the brothers/sisters. Of all the sub-
categories indicated, the first three are the
ones most referred by the subjects at-risk. 
Regarding the third category, Reasons re-
lated to curiosity and the need to know, the
subjects at-risk who felt more need to know
their genetic status were the subjects at-risk
for MJD, followed by subjects at-risk for HD
(e.g., “I need to know because I cannot stand
uncertainty”), then by subjects at-risk for
FAP, and finally, by subjects at-risk for HH
(see Table 2).
Concerning the fourth category, Reasons
related to the characteristics of the disease
(see Table 2), subjects at-risk for HH partic-
ularly reported the characteristics of the dis-
ease as a reason to perform the PST (e.g., “I
want to perform the PST because I have
many digestive problems and I have to know
whether or not it has to do with the disease”),
oppositely to the subjects at-risk for other
diseases under consideration, who reported
very few features about the disease. While
the few subjects at-risk for FAP limited the
reference to the disease to the fact of being
hereditary and that is considered reason
enough to perform the PST, subjects at-risk
for HH have seen in the characteristics of the
disease different important reasons to per-
form the PST: iron overload, liver problems,
and digestive problems.
As for the fifth category, Reasons related
to metaphors (see Table 2), low numbers have
been reported: only 5.9% of the subjects at-
risk for HD, and 1.1% of the subjects at-risk
for FAP. Although these numbers may be con-
sidered insignificant in quantitative terms,
they are related to negative aspects like night-
mare, inheritance, fear and uncertainty (e.g.,
“This disease is hell and so I have to know
whether or not I have it”).
Regarding the sixth category (Table 2),
Reasons related to references to Other dis-
eases, only subjects at-risk for HH (6.5%)
and subjects at-risk for HD (5.9%) made ref-
erences to other diseases. Epilepsy and de-
pression (e.g., “I was always depressed and
as my mother was also depressive and had
the disease, I need to know whether or not I
have it”) appear related to HD, while cirrho-
sis and kidney problems appear related to
HH.
Finally, in relation to the seventh category
(Table 2), Other reasons, only subjects at-
risk for HD (23.5%) and FAP (8.0%) seem to
be able to find other reasons to perform the
PST, at the time of the application of the PST
protocol. Of all the reasons that have been
presented by the subjects at-risk, and that
were considered valid to be referred in this
text, the ones appearing to be more consen-
sus are the ones presented in the response be-
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cause they have symptoms and in the response
the disease must end.
In conclusion, it is possible to state that
some subjects at-risk want to perform the
PST because they think they have symptoms
or because they are looking for them and,
therefore, that is a valid reason for them.
However, the results clearly indicated that
most individuals are asymptomatic. It is also
important to highlight that many subjects
cherish the idea that it is in their hands to end
the disease, and they take this task seriously,
seeking to influence others to do the same.
discussion
Before deciding to seek genetic counsel-
ing and to know their genetic status, subjects
at-risk have naturally considered their mo-
tives and it was probably the pro-counseling
reasons the ones dictating the motivation to
perform the PST. This may suggest that in
fact there is a prior self-selection to the test,
i.e. only those considering to have emotional
skills (Mikulic et al., 2015) to go through the
process, performing the test. 
The question “Which were the reasons that
led you to perform the predictive test?” gives
place to seven categories, suggesting that all
the responses obtained are homogeneous be-
cause the reasons why subjects at-risk per-
form the PST do not diverge significant ly.
From these seven categories that have been
considered regarding the motivation to per-
form the PST, there are three that seem to be
most relevant: Reasons related to the future,
Reasons related to others, and Reasons re-
lated to curiosity and the need to know. These
motivations do not differ from the ones found
by other authors (Fleming & Lopes, 2000;
Lu cas, 1998; Meissen et al., 1991; Meiser &
Dunn, 2000; Rolim et al., 2006; Sekijima et
al., 2001).
Regarding the category Reasons related to
the future, some expected subcategories were
found: to take preventive measures; to be
pregnant, to have children; to organize life,
to make decisions, to choose. The concern
with future is deeply related to the possibility
of becoming physically dependent and to die,
in case the subjects at-risk are carriers. This
scenario triggers in subjects at-risk subse-
quent concerns about others, namely their
children. Because this research relates the pe-
riod before genetic counseling, it is impor-
tant to refer that, regarding preventive mea- 
sures, many subjects at-risk wrongly believe
to be possible to prevent the disease or delay
its onset. To become pregnant or not is one
of the hardest decisions to make when the
subject at-risk thinks he/she might be a car-
rier of the disease, particularly when refer-
ring to the subjects at-risk who do not have
children yet. The threatened maternity or pa-
ternity is one of the most distressing situa-
tions for these subjects. When they decide to
have children, they have yet to make another
decision: whether or not to perform prenatal
testing (Bouchghoul et al., 2016), and this
option may only be considered feasible if the
person is willing to terminate the pregnancy
in the case of the fetus is a carrier of the mu-
tated gene. Although all of these options are
considered and assessed step by step, the re-
ality is that subjects at-risk admit they feel
overwhelmed because they must take a sig-
nificant number of important decisions in a
short space of time (Bouchghoul et al., 2016).
Ethical (Kromberg & Wessels, 2013), legal
(Freckelton, 2010, 2014), financial, logisti-
cal and material aspects become the centre of
general decisions related to life organization
as a whole, depending on what is expected to
happen to the subjects at-risk (Kromberg &
Wessels, 2013).
The category Reasons related to others
clearly includes subcategories that identify
the person and the situation that led to the de-
cision to perform a PST (Cox, 2003). Subjects
at-risk are concerned about the fact that they
have to decide whether or not to have chil-
dren because they will be a concern for a par-
ent who is not sure if it will be possible to
economically support them. Oppositely, the
same subjects at-risk may decide that children
will act as a source of support at an advanced
stage of the disease. When subjects at-risk al-
ready have children and seek for genetic
counseling, their concerns are focused on
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their future (Zagalo-Cardoso & Rolim, 2005),
because they feel that a time may come in
which they will no longer be able to give
them appropriate support. Subjects at-risk
with children also express the hope that a cure
for the disease will already be possible at the
age of the onset of the symptoms, if the chil-
dren are carriers (Rolim et al., 2006). Subjects
at-risk do not care only about their descen-
dants. They also express significant concern
with relatives who are already carriers and
who depend on their care, as the case of par-
ents, brothers/sisters, uncles/aunts, cousins,
etc. They fear that they will not be able to pro-
vide such care in a short period of time, given
the perspective that their own health will get
worse and may incapacitate them (Cox,
2003).
Regarding the category, Reasons related
to curiosity and the need to know, the sub-
jects at-risk who felt more deeply the need to
know their genetic status were the subjects
at-risk for MJD, followed by subjects at-risk
for HD, then by subjects at-risk for FAP and,
finally, by subjects at-risk for HH. These
findings are in accordance with most studies
about the motivation behind PST (Lucas,
1998; Meissen et al., 1991; Meiser & Dunn,
2000; Sekijima et al., 2001). The acquisition
of knowledge regarding the genetic status of
subjects is a way to reduce anxiety and to be
able to plan life based on that same know -
ledge (Cruz-Mariño et al., 2013; Rolim et al.,
2006). Accordingly, there is also no known
evidence that this knowledge may signifi-
cantly increase the burden among those who
are carriers of the disease’s gene, although
Wahlin and colleagues (2000) have found
high levels of suicidal ideation among indi-
viduals at-risk for HD. In general, the sub-
jects at-risk who seek genetic counseling
because they feel the need to know their ge-
netic status consider that they have the ca-
pacity to deal with the PST outcome, what- 
ever it is. However, some subjects at-risk
have not previously reflected on the implica-
tions resulting from the knowledge of their
genetic status. Therefore, this task of ex-
plaining to subjects at-risk the practical im-
plications of the PST outcome is one of the
most important ones to be carried out in the
genetic counseling process, before the disclo-
sure of the results. In the specific case of FAP,
many subjects at-risk feel the need to know
their genetic status because they are aware of
the existence of two treatments that may pre-
vent or slow the progression of the disease:
liver transplantation and the Tafamidis Medi -
cine. However, many of these subjects at-risk
confuse treatment with healing. This distinc-
tion is crucially important and it must be con-
sidered another fundamental task of the ge net-
ic counseling process for this specific dis ease.
As in the case of the subjects at-risk for
FAP, HD and MJD, the subjects at-risk for
HH also chose Reasons related to others as
one of the most important motivations to
carry out the PST in the genetic counseling.
These subjects at-risk also care about the fact
that they can transmit the disease to their
children and care about other family mem-
bers which are already ill. However, the fu-
ture is not one of the primary reasons for
performing the test, unlike subjects at-risk for
FAP, MJD and HD, since there is treatment
for HH. Accordingly, there is a future, which
will be more or less affected by the disease.
Again, and unlikely to what happens with the
subjects at-risk for FAP, HD and MJD, sub-
jects at-risk for HH choose the Reasons re-
lated to the characteristics of the disease as
one of the main motivations to perform the
PST, because the symptoms of the disease
may significantly disappear or decrease de-
pending on the available treatment, which
may result in a possible cure.
conclusions
Seven categories have emerged from the
responses given to the question aiming to
evaluate the motivations behind PST “Which
were the reasons that led you to perform the
predictive test?” However, the most import
ones are: Reasons related to the future,
Reasons related to others, and Reasons re-
lated to curiosity and the need to know. This
allows to conclude that the main reasons why
the Portuguese subjects at-risk perform the
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PST for FAP, HD and MJD are the Future,
Others, and Curiosity. Subjects at-risk for
HH indicated that the main reasons to per-
form the PST are Reasons related to others
and Reasons related to the characteristics of
the disease.
PraCtiCe iMPliCations
A better understanding of the motivations
leading the subjects at-risk for FAP, HD and
MJD to know their genetic status will allow to
adapt the genetic counseling protocol in order
to meet the needs of these individuals. Ques -
tions relating to the future, significant others
and the need to know should become part of
genetic counseling protocols. Guimarães, Se -
queiros, Skirton, and Paneque (2013) reported
that subjects at-risk who underwent the PST
for LOND’s addressed the appropriateness
and adaptation of the protocol and highlighted
the need for a greater flexibility of genetic
counseling protocols according to the coun-
selee’s personal expectations and needs. A 
personalized adaptation of the PST protocol 
can lead the subjects at-risk to redefine the
underlying motivations for its completion.
stUdy liMitations
The limitations of the present study are
mainly related to the small number of sub-
jects at-risk for MJD. However, there is an-
other important limitation that has to do with
the fact that the subjects at-risk were ques-
tioned on their motivations in a single mo-
ment, before the PST, and not during or after
the PST.
CoMPlianCe witH etHiCal standards, HUMan
stUdies and inForMed Consent
All procedures followed were in accor-
dance with the ethical standards of the re-
sponsible committee on human experimen-
tation (institutional and national) and with
the Helsinki Declaration of 1975, as revised
in 2000. Informed consent was obtained from
all patients for being included in the study. 
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taBle 1 
CHaraCterization oF tHe stUdy PartiCiPants
N = 244
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Variables
At-risk group for 
FAP, HD or MJD
(n = 213)
At-risk group for
HH
(n = 31)
Gender
Female
Male
7 (22.6%)
24 (77.4%)
Age
Minimum
Maximum
M
17
79
29.1
18
68
42.7
Place of birth
Portuguese
Foreign
199 (93.4%)
14 (6.6%)
31 (100%) 
0 (0%)
Education
Illiterate
Basic
9th grade
12th grade
University
Post-university
2 (.9%)
88 (41.3%)
5 (23.9%)
52 (24.4%)
20 (9.4%)
0 (0%)
0 (0%)
16 (51.6%)
5 (16.1%)
3 (9.7%)
7 (22.6%)
0 (0%)
Disease
FAP
HD
MJD
HH
174 (81.7%)
34 (16.0%)
5 (2.3%)
31(100%)
TABle 2 
CATegORIeS ReSUlTIng FROM InTeRVIeWS
TABle 3 
SUMMARy OF THe SUBCATegORIeS UnDeR THe 2nD CATegORy (ReASOnS RelATeD TO OTHeRS)
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“Which were the reasons that led 
you to perform the predictive test?"
FAP HD MJD HH
Categories (Reasons related to...) n % n % n % n %
1.- The future
2.- Others
3.- Curiosity and the need to know  
4.- The characteristics of the disease 
5.- Metaphors 
6.- Other diseases 
7.- Other reasons 
116          64.8
107 61.5
57 31.8
5 2.9
2 1.1
0 0.0
14 8.0
20 58.8
14 41.2
14 41.2
1 2.9
2 5.9
2 5.9
8 23.5
4 80
1 20
4 80
0 0 
0 0 
0 0
0 0 
6 19.4
22 71.0
5 16.1
20 64.5
0 0.0
2 6.5
1 3.2
Total 179          100 34             100 5             100 30            100
Category Subcategories n
Reasons related to
others (144)
(1) Because of someone else
(2) Instigated by others
(3) Because someone has the disease
(4) Because someone died with the disease
43
49
40
12
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